132 related articles for article (PubMed ID: 21240253)
21. CRISP3 expression drives prostate cancer invasion and progression.
Volpert M; Furic L; Hu J; O'Connor AE; Rebello RJ; Keerthikumar S; Evans J; Merriner DJ; Pedersen J; Risbridger GP; McIntyre P; O'Bryan MK
Endocr Relat Cancer; 2020 Jul; 27(7):415-430. PubMed ID: 32357309
[TBL] [Abstract][Full Text] [Related]
22. Expression patterns of candidate susceptibility genes HNF1β and CtBP2 in prostate cancer: association with tumor progression.
Debiais-Delpech C; Godet J; Pedretti N; Bernard FX; Irani J; Cathelineau X; Cussenot O; Fromont G
Urol Oncol; 2014 May; 32(4):426-32. PubMed ID: 24332637
[TBL] [Abstract][Full Text] [Related]
23. Investigation of miR-21, miR-141, and miR-221 expression levels in prostate adenocarcinoma for associated risk of recurrence after radical prostatectomy.
Zheng Q; Peskoe SB; Ribas J; Rafiqi F; Kudrolli T; Meeker AK; De Marzo AM; Platz EA; Lupold SE
Prostate; 2014 Dec; 74(16):1655-62. PubMed ID: 25252191
[TBL] [Abstract][Full Text] [Related]
24. Subcellular localization of p27 and prostate cancer recurrence: automated digital microscopy analysis of tissue microarrays.
Ananthanarayanan V; Deaton RJ; Amatya A; Macias V; Luther E; Kajdacsy-Balla A; Gann PH
Hum Pathol; 2011 Jun; 42(6):873-81. PubMed ID: 21292307
[TBL] [Abstract][Full Text] [Related]
25. PYGOPUS2 expression in prostatic adenocarcinoma is a potential risk stratification marker for PSA progression following radical prostatectomy.
Kao KR; Popadiuk P; Thoms J; Aoki S; Anwar S; Fitzgerald E; Andrews P; Voisey K; Gai L; Challa S; He Z; Gonzales-Aguirre P; Simmonds A; Popadiuk C
J Clin Pathol; 2018 May; 71(5):402-411. PubMed ID: 28924059
[TBL] [Abstract][Full Text] [Related]
26. High Gleason grade carcinoma at a positive surgical margin predicts biochemical failure after radical prostatectomy and may guide adjuvant radiotherapy.
Savdie R; Horvath LG; Benito RP; Rasiah KK; Haynes AM; Chatfield M; Stricker PD; Turner JJ; Delprado W; Henshall SM; Sutherland RL; Kench JG
BJU Int; 2012 Jun; 109(12):1794-800. PubMed ID: 21992536
[TBL] [Abstract][Full Text] [Related]
27. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy.
Li R; Wheeler T; Dai H; Frolov A; Thompson T; Ayala G
Am J Surg Pathol; 2004 Jul; 28(7):928-34. PubMed ID: 15223964
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of prognostic factors after radical prostatectomy in pT3b prostate cancer patients in Japanese population.
Inoue T; Kinoshita H; Terada N; Kobayashi T; Yamasaki T; Matsui Y; Kamba T; Inui H; Sugi M; Matsuda T; Ogawa O
Jpn J Clin Oncol; 2015 Aug; 45(8):780-4. PubMed ID: 25981623
[TBL] [Abstract][Full Text] [Related]
29. Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer.
Bañez LL; Sun L; van Leenders GJ; Wheeler TM; Bangma CH; Freedland SJ; Ittmann MM; Lark AL; Madden JF; Hartman A; Weiss G; Castaños-Vélez E
J Urol; 2010 Jul; 184(1):149-56. PubMed ID: 20478579
[TBL] [Abstract][Full Text] [Related]
30. Modification of the pT2 substage classification in prostate adenocarcinoma.
Ettel M; Kong M; Lee P; Zhou M; Melamed J; Deng FM
Hum Pathol; 2016 Oct; 56():57-63. PubMed ID: 27251951
[TBL] [Abstract][Full Text] [Related]
31. Prognostic value of Ki67 in localized prostate carcinoma: a multi-institutional study of >1000 prostatectomies.
Tretiakova MS; Wei W; Boyer HD; Newcomb LF; Hawley S; Auman H; Vakar-Lopez F; McKenney JK; Fazli L; Simko J; Troyer DA; Hurtado-Coll A; Thompson IM; Carroll PR; Ellis WJ; Gleave ME; Nelson PS; Lin DW; True LD; Feng Z; Brooks JD
Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):264-70. PubMed ID: 27136741
[TBL] [Abstract][Full Text] [Related]
32. Role of microvessel density in predicting recurrence in pathologic Stage T3 prostatic adenocarcinoma.
Gettman MT; Pacelli A; Slezak J; Bergstralh EJ; Blute M; Zincke H; Bostwick DG
Urology; 1999 Sep; 54(3):479-85. PubMed ID: 10475358
[TBL] [Abstract][Full Text] [Related]
33. The Impact of Downgrading from Biopsy Gleason 7 to Prostatectomy Gleason 6 on Biochemical Recurrence and Prostate Cancer Specific Mortality.
Ham WS; Chalfin HJ; Feng Z; Trock BJ; Epstein JI; Cheung C; Humphreys E; Partin AW; Han M
J Urol; 2017 Apr; 197(4):1060-1067. PubMed ID: 27847296
[TBL] [Abstract][Full Text] [Related]
34. Androgen receptor mediated epigenetic regulation of CRISP3 promoter in prostate cancer cells.
Pathak BR; Breed AA; Deshmukh P; Mahale SD
J Steroid Biochem Mol Biol; 2018 Jul; 181():20-27. PubMed ID: 29477539
[TBL] [Abstract][Full Text] [Related]
35. Matrix metalloproteinases and angiogenic factors: predictors of survival after radical prostatectomy for clinically organ-confined prostate cancer?
Boxler S; Djonov V; Kessler TM; Hlushchuk R; Bachmann LM; Held U; Markwalder R; Thalmann GN
Am J Pathol; 2010 Nov; 177(5):2216-24. PubMed ID: 20889560
[TBL] [Abstract][Full Text] [Related]
36. Overexpression of ERG and Wild-Type PTEN Are Associated with Favorable Clinical Prognosis and Low Biochemical Recurrence in Prostate Cancer.
Kim SH; Kim SH; Joung JY; Lee GK; Hong EK; Kang KM; Yu A; Nam BH; Chung J; Seo HK; Park WS; Lee KH
PLoS One; 2015; 10(4):e0122498. PubMed ID: 25897494
[TBL] [Abstract][Full Text] [Related]
37. Genetic and epigenetic SLC18A2 silencing in prostate cancer is an independent adverse predictor of biochemical recurrence after radical prostatectomy.
Sørensen KD; Wild PJ; Mortezavi A; Adolf K; Tørring N; Heebøll S; Ulhøi BP; Ottosen P; Sulser T; Hermanns T; Moch H; Borre M; Ørntoft TF; Dyrskjøt L
Clin Cancer Res; 2009 Feb; 15(4):1400-10. PubMed ID: 19228741
[TBL] [Abstract][Full Text] [Related]
38. Limited value of perineural invasion in radical prostatectomy specimens as a predictor of biochemical recurrence in Japanese men with clinically localized prostate cancer.
Miyake H; Sakai I; Harada K; Eto H; Hara I
Hinyokika Kiyo; 2005 Apr; 51(4):241-6. PubMed ID: 15912782
[TBL] [Abstract][Full Text] [Related]
39. Validation of the prognostic value of NF-κB p65 in prostate cancer: A retrospective study using a large multi-institutional cohort of the Canadian Prostate Cancer Biomarker Network.
Grosset AA; Ouellet V; Caron C; Fragoso G; Barrès V; Delvoye N; Latour M; Aprikian A; Bergeron A; Chevalier S; Fazli L; Fleshner N; Gleave M; Karakiewicz P; Lacombe L; Lattouf JB; van der Kwast T; Trudel D; Mes-Masson AM; Saad F;
PLoS Med; 2019 Jul; 16(7):e1002847. PubMed ID: 31265453
[TBL] [Abstract][Full Text] [Related]
40. Akt Activation Correlates with Snail Expression and Potentially Determines the Recurrence of Prostate Cancer in Patients at Stage T2 after a Radical Prostatectomy.
Chen WY; Hua KT; Lee WJ; Lin YW; Liu YN; Chen CL; Wen YC; Chien MH
Int J Mol Sci; 2016 Jul; 17(8):. PubMed ID: 27455254
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
